anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject composition, composed of a live microorganism for controlling the intestinal function represented by a butyric acid bacterium and glucomannan, excellent in bioavailability and therapeutic effects and useful for acute gastroenteritis, functional foods, etc. CONSTITUTION:This bacterial composition is obtained by blending (A) 1 pt. wt. live microorganism for controlling the intestinal function represented by a butyric acid bacterium such as Clostridium butyricum Miyairi 588 (FERM P-2789) with (B) preferably 0.2-10 pts.wt. glucomannan. Furthermore, the daily dose of this composition is preferably within the range of 1X10<6> to 1X10<10> cells expressed in terms of cell number.
BACKGROUND: The comparative outcomes with immediate, staged in-hospital, and staged out-of-hospital complete revascularization for patients with ST-segment-elevation myocardial infarction and multivessel disease remain unclear.
METHODS AND RESULTS: An electronic search of MEDLINE, SCOPUS, and Cochrane databases was performed through August 2023 for randomized trials evaluating immediate, staged in-hospital, and staged out-of-hospital complete revascularization for patients with ST-segment-elevation myocardial infarction and multivessel disease. The primary outcome was major adverse cardiac events (MACEs). The final analysis included 9 trials with 4270 patients. The weighted follow-up duration was 13.8 months. On pairwise meta-analysis, there were no statistically significant differences between immediate versus staged nonculprit percutaneous coronary intervention (PCI) in MACEs (odds ratio, 0.79 [95% CI, 0.54-1.16]). Network meta-analysis showed that there was no statistically significant difference in MACEs with staged in-hospital nonculprit PCI (odds ratio, 1.29-[95% CI, 0.91-1.82]) compared with immediate nonculprit PCI, while there were higher odds of MACEs with out-of-hospital nonculprit PCI (odds ratio, 1.67-[95% CI, 1.21-2.30]) compared with immediate nonculprit PCI. Compared with immediate nonculprit PCI, there were higher odds of ischemia-driven repeat revascularization with staged out-of-hospital nonculprit PCI (odds ratio, 2.26-[95% CI, 1.37-3.72]), but not with in-hospital staged nonculprit PCI. There were no significant differences for the other outcomes among the 3 strategies.
CONCLUSIONS: Among patients with ST-segment-elevation myocardial infarction with multivessel disease, an immediate nonculprit PCI approach was associated with similar clinical outcomes to the staged nonculprit PCI approach. The staged out-of-hospital nonculprit PCI approach was associated with a higher incidence of MACEs compared with the other strategies, which was driven by higher risk for ischemia-driven repeat revascularization.
PURPOSE: Mineral powder obtained by calcining mineral stone, germanium ore, jade stone, amethyst and kiyoseki stone as main minerals and quartz porphyry, kaolin and loess as auxiliary minerals and then grounding is provided. It is effective in inhibiting proliferation of cancer cells and has antifatigue properties. CONSTITUTION: Mineral stone, germanium ore, jade stone, amethyst and kiyoseki stone are mixed in the same ratio, ground into 325 to 50meshes and introduced into a calcining furnace. One or more auxiliary ores selected from quartz porphyry, kaolin and loess are ground into 325 to 500meshes, and introduced into the calcining furnace. The ores are heated at 600 to 1,000deg.C for 11 to 13hr and cooled at room temperature for 11 to 13hr. The heating and cooling procedures are repeated 3 to 9 times and the calcined ores are finally ground into 500 to 2,500meshes.
A simultaneous detection method for two cardiac disease protein biomarkers present in serum samples on a single planar gold chip using surface plasmon resonance (SPR) is described. The detection of N-terminal pro-brain natriuretic peptide (NT-proBNP) and tumor necrosis factor α (TNF-α), which are known as acute myocardial infarction (AMI) biomarkers, with predetermined clinically relevant concentrations was performed using mixed aptamers specific to each protein tethered on a single gold surface. After the binding of NT-proBNP and/or TNF-α to the mixed aptamers, an antibody specific to each target protein was injected to form a surface sandwich complex to improve selectivity. In order to adjust the dynamic ranges in the known clinically relevant concentration significantly different for NT-proBNP (0.13-0.24 nM) and TNF-α (0.5-3 pM), the surface density ratios of the corresponding pair of aptamer and antibody were first systematically determined, which were the 1:1 mixed aptamer chip with 40 nM anti-NT-proBNP and 100 nM anti-TNF-α. This allowed to establish the distinct dynamic ranges of 0.05-0.5 nM for NT-proBNP and 0.1-5 pM for TNF-α in a buffer, along with detection and quantification limits of 0.03 and 0.19 nM for NT-proBNP and 0.06 and 0.21 pM for TNF-α, respectively. The changes in refractive unit (RU) values observed when exposing both proteins at different concentrations alongside the corresponding fixed concentration of antibodies onto the 1:1 mixed aptamer chip were then correlated to the sum of RU values measured when using the injection of individual protein for evaluating each protein concentration. With a complete characterization of the simultaneous quantification of two protein concentrations in the buffer, the mixed aptamer chip was finally employed for direct measurements of NT-proBNP and TNF-α concentrations in undiluted serum samples from healthy controls and AMI patients. The results of simultaneous SPR measurements for the two proteins in the serum samples were further compared to the individual protein concentration results using an enzyme-linked immunosorbent assay.
Consecutive patients were enrolled and were divided into Group 1(the formation time of phytobezoars was less than 7 days), Group 2(the formation time of phytobezoars was from 7 days to 14 days) and Group 3 (the formation time of phytobezoars was more than 14 days) according to the formation time of phytobezoars and each group was subdivided into control group (who refused to diet Coca-Cola and chose emergent fragmentation with gastroscopy) and intervention Group (who had a willing to diet Coca-Cola) from 1st Jan, 2017 to 1st Dec 2021. The current protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Qingdao University (QYFYWZLL 26293). The patients in intervention group all dieted Coca-Cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to personal health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The Coca-Cola dieting period of intervention group 1 was 3 days, intervention group 2 was 5 days and intervention group 3 was 7 days. The patients would go through an endoscopy once the Coca-Cola dieting therapy was over. The patients who chose emergently endoscopic fragmentation was enrolled in control Group. All patients endorsed the digital informed consent and bring the medical records before endoscopy. Statistical analysis was performed with SPSS version 22(IBM, Inc. Armonk, NY, USA). ANOVA or independent samples t-test was used for analysis of continuous variables. P \< 0.05 was taken as statistical meaning.
Activated PI3K delta syndromes (PI3Kδ) (APDS type 1 and type 2) are combined immunodeficiencies with variable clinical manifestations caused by heterozygous gain-of-function mutations of the PIK3CD gene. APDS is a very young onset disease, most clinical manifestations appear in pediatric age. Patients may experience severe, disabling, and life-threatening clinical manifestations. Additionally, they may exhibit autoimmunity in addition to immune deficiency. APDS patients present a high risk of developing tumors especially B lymphomas. Hematopoietic stem cell transplantation (HSCT) is the only curative option and, given the risks, may be considered for patients with severe APDS (including those who have developed lymphoma). HSCT is curative, but carries a 10 to 20% mortality risk and cannot guarantee reversibility of organ damage. Positive data from the phase II/III study of the PI3Kδ selective inhibitor leniolisib met the co-primary criteria of reduced lymph node size and increased percentage of B naïve cells in patients with APDS. In addition, safety data from the study showed that leniolisib was well tolerated by participants. The drug is also under review by the European Medicines Agency and a marketing authorization for APDS patients older than 12 years old will be soon available. In the meantime the access to this drug is available by compassionate use for patients older than 12 years old.

In this context, it will be interesting to evaluate the clinical and biological profile of these patients before and after leniolisib treatment in order to identify useful biomarkers for the follow up of the disease. In addition, carful long-term monitoring of patients under PI3Kδ inhibitors is mandatory to detect adverse effects of iatrogenic overinhibition of the PI3K pathway.
Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
Intrapartum fetal hypoxia is related to long-term morbidity and mortality of the fetus and the mother. Fetal surveillance is extremely important to minimize the adverse outcomes arising from fetal hypoxia during labour. Several methods have been used in current clinical practice to monitor fetal well-being. For instance, biophysical technologies including cardiotocography, ST-analysis adjunct to cardiotocography, and Doppler ultrasound are used for intrapartum fetal monitoring. However, these technologies result in a high false-positive rate and increased obstetric interventions during labour. Alternatively, biochemical-based technologies including fetal scalp blood sampling and fetal pulse oximetry are used to identify metabolic acidosis and oxygen deprivation resulting from fetal hypoxia. These technologies neither improve clinical outcomes nor reduce unnecessary interventions during labour. Also, there is a need to link the physiological changes during fetal hypoxia to fetal monitoring technologies. The objective of this article is to assess the clinical background of fetal hypoxia and to review existing monitoring technologies for the detection and monitoring of fetal hypoxia. A comprehensive review has been made to predict fetal hypoxia using computational and machine-learning algorithms. The detection of more specific biomarkers or new sensing technologies is also reviewed which may help in the enhancement of the reliability of continuous fetal monitoring and may result in the accurate detection of intrapartum fetal hypoxia.
Chronic pain is a prevalent health condition that imposes a significant burden on the global health system. Health literacy is a determinant of the quality of pain management which directly impacts public and individual health. However, the existing health literacy measurements have predominantly focused on medical models stemmed from Western culture and the knowledge of non-Western health models has largely been neglected. This review scopes refereed health literacy publications with regard to traditional Chinese medicine and chronic pain to explore and identify 1) the conceptual basis underlying the development of traditional Chinese medicine health literacy in this area, and 2) measurement tools used in this area and their associated psychometric qualities. Twenty-eight journal articles were assessed and the results showed that most studies' conceptual frameworks were unable to cover three key health literacy aspects defined by the World Health Organization (access, understand, and apply). Furthermore, the identified health literacy measurement tools generally lacked rigorous psychometric evaluation. Future studies should focus on exploring a comprehensive model that encompasses various health models and developing measurement tools with more culturally representative psychometric assessments.
The invention comprises 2-[b -(4-pyridyl)ethyl]-6-methyl-4 : 5-dihydro-3-pyridazinone and its preparation by reacting b -(4-pyridyl) ethyl hydrazine with laevulinic acid or an alkyl ester thereof. The product is conveniently separated from the reaction mixture by removing water or alcohol formed in the reaction and distilling off the reaction product. The product is useful as a potentiator of drugs affecting the central nervous system (see Group VI). Specification 884,606 is referred to.ALSO:Pharmaceutical preparations affecting the central nervous system contain as a potentiating agent the compound 2-[b -(4-pyridyl)ethyl]-6-methyl - 4,5 - dihydro - 3 - pyridazinone. Suitably, a drug such as pentobarbital, hexobarbital, chloral hydrate, chlorpromazine, mephenesin, strychnine or diphenylhydantoin is increased in effectiveness or duration of activity by administration with the pyridazinone compound, preferably in conjunction with pharmaceutical excipients in the form of tablets, capsules, powders, elixirs, suspensions or injectable menstrua such as water or aqueous polyhydric alcohols. Specification 884,606 is referred to.
The invention relates to a belly hot-compress weight-losing drug for over-nutrition obesity and a preparation method thereof. The belly hot-compress weight-losing drug is prepared by mixing a component A and a component B. The component A comprises fortune eupatorium herb 20g, angelica roots 15g, Chinese atractylode rhizome 15g, radix angelicae pubescentis 10g, elecampane 10g, wild pepper 5g, folium artemisiae argyi 5g, cassia twig 15g, Chinese angelica 30g, ligusticum wallichii 15g, asarum 10g, rhizoma sparganii 10g, curcuma zedoary 10g, frankincense 5g, myrrh 5g and clove 5g. The component B comprises borneol 5g. The component B is added into the component A to be stirred and mixed to prepare the hot-compress weight-losing drug. The belly hot-compress weight-losing drug can permeate into human body tissues through belly hot compressing and massage to the human body belly, promote consumption and conversion of subcutaneous fat and achieve the weight-losing purpose. The belly hot-compress weight-losing drug is suitable for weight loss and hot-compress application of belly obese people caused by over nutrition.
Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
PROBLEM TO BE SOLVED: To improve the hemostasis effect, the biocompatibility and safety against virus, and expand the application range by incorporating a fibrin web comprising fibrinogen without containing a dialyzable component in a wound covering article having flexibility, of which the base is fibrin. SOLUTION: This wound covering article is biodegradable and flexible, and of which the base is fibrin, and one containing a fibrin web of which the dialyzable component is almost totally or totally removed, is used. In this case, the fibrin web preferably is combined with a biodegradable carrier substance firmly. Also, the fibrin web preferably contains glycerol of 10-80 wt.% per fibrin unit. In addition, at the time of the manufacture, a method wherein after dialyzing a fibrinogen solution, the flexible fibrin web is made to react with a thorombin solution, and the flexible fibrin web is freeze-dried, is preferable. In the meantime, as the biodegradable carrier substance, natural or synthetic colagen and keratin or the like are preferable.
The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.

Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.

The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.

  


Information for the Patient

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.
The present invention relates to polypeptides having a brain-localizing activity, molecules comprising these polypeptides, and pharmaceutical agents that confer brain-localizing activity. The present inventors are the first to reveal amino acid motif sequences involved in brain-localizing activity. Polypeptides that comprise such motif sequences and have brain localizing activity were discovered as follows: DNAs encoding polypeptides comprising random amino acid sequences were synthesized, and incorporated into a phage library. The phage library produced was used to screen for polypeptides having brain-localized activity, which yielded such several polypeptides. These polypeptides comprised common sequences, which lead to the successful discovery of amino acid motif sequences involved in brain-localizing activity. The polypeptides of the present invention comprising the motif sequences specifically bind to cerebrovascular endothelial cells, and induce a transcellular pathway that enables brain-specific targeting and transport of substances in the cerebral parenchyma, which was not possible prior to the present invention.
The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
A computing system may be provided for applying machine learning to a data collection to improve a surgical outcome. The computing system may comprise a processor. The processor may be configured to perform a number of actions. An indication that an operational behavior of a surgical device may be suboptimal may be determined from a data collection that may include one or more biomarkers. A model that may optimize and/or improve the behavioral operation of the surgical device to improve a surgical outcome may be determined using machine learning and the data collection. The model may be updated using feedback given by a healthcare provider to improve the model. The control program update may be determined using the model and the data collection. The control program update may be configured to alter a manner in which a control program operates the surgical device during the surgical procedure. The control program update may be sent to the surgical device.
The development of point-of-care (POC) diagnostics devices for circulating tumor cells (CTCs) detection plays an important role in the early diagnosis of pheochromocytoma (PCC), especially in a low-resource setting. To further realize the rapid, portable, and high-throughput detection of CTCs, an Au@CuMOF cascade enzyme-based microfluidic device for instant point-of-care detection of CTCs was constructed by combining a smartphone application and a commercial portable glucose meter (PGM). In this microfluidic system, DOTA and norepinephrine (NE) modified Au@CuMOF signal probes and Fe3O4@SiO2 capture probes were used for the dual recognition and capture of rare PCC-CTCs. Then, the targeted binding of the Au@CuMOF cascade nanozymes to the CTCs endowed the cellular complexes with multienzyme mimetic activities (i.e., glucose oxidase-like and peroxidase-like activity) to catalyze glucose reduction as signal output for colorimetric and personal glucose meter (PGM) dual-mode detection of CTCs. The developed method has a linear range of 4 to 105 cells mL-1 and a detection limit of 3 cells mL-1. This method allows the simultaneous detection of six samples and demonstrates good applicability for CTCs detection in whole blood samples. More importantly, the combination of PGM, smartphone app and array microfluidic chips enables the rapid, portable, and high-throughput diagnoses of PCC, and providing provide a convenient and reliable alternative to traditional liquid biopsy diagnosis of various cancers.
PURPOSE:To produce the titled vaccine, by culturing a human hepatoma cell system capable of producing a hepatitis virus B surface antigen (HBsAg) at a high rate, and collecting the HBsAg from the cultured liquid. CONSTITUTION:The tissue of human hepatoma is cultured in a culture liquid added with serum (e.g. a medium containing amino acids, vitamins, inorganic salts, etc.) to obtain the cell system of human hepatoma [e.g. hepatoma cell system cmposed of huSP (the form of the cell, epithelial cell; origin of the cell, human hepatoma tissue; number of chromosomes, 69; the number of sites of chromosome-insertion in HBV, about 9 per one haploid; productivity of HBsAg, very high]. The obtained cell is inoculated in a serum-containing culture medium, and cultured preferably in air containing CO2 in high concentration at 32-42 deg.C. The supernatant liquid of the cultured product is collected, and the HBsAg is separated from the supernatant liquid and purified to obtain the objective hepatitis virus B vaccine.